natgillin/translations-raw huggingface dataset:
Food such as fruit and fruit juices contains large amounts of fructose, but in particular also sucrose, which is cleaved to fructose and glucose in the body. In the following, the term 'fructose containing' is used to mean all substances and foodstuffs that either contain fructose in pure form or from which fructose can be released in the digestive tract. 
Glukoza izomeraze za uporabu u skladu sa zahtjevom 1, naznačena time, što liječenje obuhvaća smanjenje ili sprečavanje pojave simptoma intolerancije fruktoze kod subjekata čovjeka ili životinje nakon unosa navedenog subjekta fruktoze ili supstance ili prehrambenog proizvoda koji sadrži fruktozu u čistom obliku ili obliku od kojih fruktoza može biti puštena u probavni trakt.
at least one viscosity-increasing agent, which, with the assistance of a necessary minimum quantity of an aqueous liquid, forms a gel with the extract obtained from the dosage form, which gel preferably remains visually distinguishable when introduced into a further quantity of an aqueous liquid, 
(b) barem jedno sredstvo za povećanje viskoziteta, koje tvori gel u ekstraktu dobivenom iz oblika davanja pomoću potrebne najmanje količine vodene tekućine, koji gel prvenstveno kod unošenja u daljnju količinu vodene tekućine ostaje vizualno razlikovnim,
32, 33 and 34, wherein said antibody increases ITIM phosphorylation of FcYRIIB of Daudi cells about 4 to 10-fold in comparison to Daudi cells not treated with said antibody. 
32, 33 i 34, gdje navedeno protutijelo povećava fosforiliranje ITIM u FcyRIIB kod Daudi stanica otprilike 4 do 10 puta u usporedbi s Daudi stanicama neobrađenim navedenim protutijelom.
The solid composition of claim 28, used for the diagnosis of right colon adenomas, right colon polyps and/or interval cancers. 
Čvrsti pripravak u skladu s patentnim zahtjevom 12, naznačen time što se upotrebljava kod procjenjivanja adenoma desnog debelog crijeva, polipa desnog debelog crijeva i/ili intervalnih rakova.
The resultant gels are distinguished by a turbid appearance, which provides the potential abuser with an additional optical warning and discourages him/her from administering the gel parenterally. 
Tako dobiveni gelovi odlikuju se mutnim izgledom, koji potencijalnog zlorabitelja dodatno optički upozorava i odvraća od parenteralne primjene gela.
The compound according to claim 8 wherein R1 is C1-6alkyl, R5 is H, R6 is H or C1-6alkyl, and R3 is aryl being a monocyclic, bicyclic or tricyclic carbon ring of up to seven members in each ring and wherein at least one ring is aromatic, said aryl being optionally substituted with from one to three substituents selected from the group consisting of methylenedioxy, hydroxy, C1-6-alkoxy, halogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, trifluoromethyl, trifluoromethoxy, -NO2, -NH2, -NH(C1-6-alkyl), -N(C1-6-alkyl)2, -NH-acyl, and - N(C1-6-alkyl)acyl, said acyl group being a saturated aliphatic hydrocarbon group having from one to six carbon atoms attached to a carbonyl moiety. 
Spoj u skladu s patentnim zahtjevom 8, gdje Ri je CLg-alkil, Ra, Rs je H, Rs je H ili Crcalkil, a Rs je aril koji je monociklički, biciklički ili triciklički ugljični prsten s do sedam članova u svakom prstenu, te gdje je najmanje jedan prsten aromatski, a navedeni aril je izborno supstituiran s jednim do tri supstituenta, koje se bira iz skupine koju čine metilendioksi, hidroksi, Ci.s-alkoksi, halogen, Cig-alkil, Cog-alkenil, C>s-alkinil, trifluormetil, trifluormetoksi, -NO», -NH, -NH(C1.6-alkil), -N(C,.6-alkil),, -NH-acil, te -N(Ci.g-alkiljacil, gdje je navedena acilna skupina zasićena alifatska ugljikovodična skupina s jednim do šest atoma ugljika, vezana na karbonilni ostatak.
The method according to claim 1, wherein additionally the level of methylated genomic DNA of RASSF2A (SEQ ID N0:16), is measured, preferably the methylation of the genomic DNA is measured at least at one cytosine selected from the group consisting of positions 21, 28, 30, 37 and 39 of SEQ ID NO: 32 for SEPTIN9 (SQ ID NO: 1) and positions 25, 29, 46, 52, 58, 70, 74, 79 and 89 of SEQ ID NO: 34 for RASSF2A (SEQ ID NO: 16). 
Metoda u skladu sa patentnim zahtjevom 1, gdje je dodatno nivo metilirane genomske DNK od RASSF2A (SEK ID BR:16), izmjeren, poželjno metilacija genomske DNK je izmjerena najmanje na jednom citozinu koji je odabran od grupe koja se sastoji od pozicija 21, 28, 30, 37 139 sa SEK ID BR: 32 za SEPTIN9 (SEK ID BR: 1) i pozicije 25, 29, 46, 52, 58, 70, 74, 79 1 89 sa SEK ID BR: 34 za RASSF2A (SEK ID BR: 16).
A compound according to claim 1, wherein R1 is a piperidine or pyrrolidine ring, optionally substituted with one or two alkyl groups. 
Spoj prema patentnom zahtjevu 5, naznačen time da je piperidinski ili pirolidinski prsten supstituiran s jednom ili dvije alkilne skupine.
A pharmaceutical formulation for use in the treatment of respiratory disease according to any of Claims 1 to 7 wherein the respiratory disease is asthma. 
Farmaceutska formulacija namijenjena upotrebi u liječenju bolesti dišnog sustava u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što je bolest dišnog sustava astma.
deletion of an endogenous nucleic acid sequence, wherein the deletion ranges from about 40 kb to about 60 kb, from about 60 kb to about 80 kb, from about 80 kb to about 100 kb, from about 100 kb to about 150 kb, from about 150 kb to about 200 kb, from about 200 kb to about 300 kb, from about 300 kb to about 400 kb, from about 400 kb to about 500 kb, from about 500 kb to about 1 Mb, from about 1 Mb to about 1.5 Mb, from about 1.5 Mb to about 2 Mb, from about 2 Mb to about 2.5 Mb, or from about 2.5 Mb to about 3 Mb; 
deleciju sekvence endogene nukleinske kiseline, naznačeno time da je delecija u opsegu od oko 40 kb do oko 60 kb, od oko 60 kb do oko 80 kb, od oko 80 kb do oko 100 kb, od oko 100 kb do oko 150 kb, od oko 150 kb do oko 200 kb, od oko 200 kb do oko 300 kb, od oko 300 kb do oko 400 kb, od oko 400 kb do oko 500 kb, od oko 500 kb do oko 1 Mb, od oko 1 Mb do oko 1.5 Mb, od oko 1.5 Mb do oko 2 Mb, od oko 2 Mb do oko 2.5 Mb, ili od oko 2.5 Mb do oko 3 Mb;
The "film" thickness of the top coating after drying was about 8 µm. 
Debljina,,filma" gornjeg sloja nakon sušenja iznosila je oko 8 um.
A microfluidic device for visual analysis of immobilized cells comprising a slide and a part in which at least one groove is present, said part being a pad of silicone and being reversibly coupled to the slide due to spontaneous adhesion between said pad and said slide, said slide and said part being such that their joining defines a microchannel, said microchannel being accessible from a top surface of the device via through holes present in said part, wherein at least the area on a surface of said slide facing said microchannel is functionalized with a hydrophilic nanostructured metal oxide film of thickness comprised between 20 nm and 200 nm with a wettability contact angle lower than 10°, wherein the nanostructured metal oxide film has a porous structure with a mass density from about ½ to about 1/10 of the mass density of the bulk oxide corresponding to the nanostructured metal oxide film. 
HR P20140042 T1 PATENTNI ZAHTJEVI Mikrofluidni uređaj koji obuhvaća stakalce 1 dio u kojem se nalazi barem jedan utor, taj dio je mekani podložak od silikona, neoprena ili polidimetilsiloksana (PDMS) 1 reverzibilno je spojen sa stakalcem, to stakalce i dio su takvi da njihovim spajanjem nastaje mikrokanal, taj mikrokanal se ne pruža duž cijele dužine dijela u kojem se nalazi i dostupan je s gornje površine uređaja preko rupa, naznačeno time što je barem područje na površini stakalca koja je okrenuta prema mikrokanalu funkcionalizirano filmom hidrofilnog nano-strukturiranog metalnog oksida i time što je taj oksid obrađen plazmom radi dobivanja kontaktnog kuta ne većeg od 10".
The cells were dye loaded (Ca2+-kit from Molecular Devices, and according to their instructions) at 37° C. in a 5% CO2 incubator at 95% humidity. 
Stanice su obojene (Ca*'-komplet od Molecular Devices, prema njihovim uputama) na 37%C u 5% CO, inkubatoru uz vlažnost od 95%.
A pharmaceutical composition comprising a compound of any one of claims 1-8, and a pharmaceutically acceptable carrier, adjuvant or vehicle. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema zahtjevu 1 1 farmaceutski prihvatljiv nosač, pomoćno sredstvo 1li prijenosno sredstvo.
The method of claim 1, wherein the patient experiences an improvement in FEV1 for at least 15 days after the administration period ends, as compared to the FEV1 of the patient prior to the administration period. 
Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-9, naznačen time, što poboljšanje FEV1 pacijenta iznosi najmanje 5% u odnosu na FEV1 pacijenta prije liječenja.
The method of claim 10 wherein the energy savings system does not monitor characteristics of a load to which it is connected. 
Metodu zahtjeva 10 gdje sustav uštede energije ne nadzire karakteristike opterećenja na koje je spojen.
The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible. 
Kladribinska farmaceutska formulacija, namijenjena upotrebi u liječenju multiple skleroze, naznačena time što formulaciju treba primijeniti oralno, prema sljedećim koracima, niže: (i)
The compound, tautomer or pharmaceutically acceptable salt thereof for use, according to claim 7 wherein the disease or disorder is Crohn's disease. 
Spoj, njegov tautomer ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što je bolest 1li poremećaj Crohnova bolest.
Biotage™ chromatography refers to purification carried out using equipment sold by Dyax Corporation (either the Flash 40i or Flash 150i) and cartridges pre-packed with KPSil. 
BiotageTM kromatografija odnosi se na pročišćavanje provedeno aparaturom nabavljenom od strane firme Dyax Corporation (bilo Flash 40i ili Flash 150i), a ulošci su prethodno napunjeni masom KPSil.
A locking panel socket (1) as claimed in Claim 1 or Claim 2, in which the locking mechanism (12) is a pivoting latch plate that has an aperture therethrough with upper and lower edges that allow a power pin to enter said recess (10') but which dig in to the power pin when this is pulled in the opposite direction. 
Panel utičnica (1) sa zaključavanjem prema zahtjevu 1 ili zahtjevu 2, naznačena time da je mehanizam (12) za zaključavanje okretna pločasta reza koja ima otvore na gornjim 1 donjim krajevima koji omogućavaju da kontaktni štift uđe u navedene utore (10') koji prodiru u kontaktni štift kada se povlači u suprotnom smjeru.
at least one active agent, to form a composition; shaping the composition to form an extended release matrix formulation; and curing said extended release matrix formulation comprising at least a curing step wherein said polyethylene oxide at least partially melts. 
(2) barem jednog aktivnog agensa, kako bi se formirao sastav; (b) oblikovanje sastava kako bi se formirala formulacija matrice s produljenim otpuštanjem; i (c) stvrdnjavanje navedene formulacije matrice s produljenim otpuštanjem koje sadrži barem korak stvrdnjavanja gdje se navedeni polietilen oksid barem djelomično rastopi.
wherein the upstream and downstream primers do not amplify the target molecule independently of the oligonucleotide, when the oligonucleotide is contacted with the recombinase, it invades the double-stranded nucleic acid target molecule, thereby rendering the complementary region of the target molecule and adjacent regions single-stranded thereby allowing the primers access to bind to complementary single stranded DNA on the target molecule. 
dovođenje u kontakt oligonukleotida (ii) s rekombinazom kako bi se omogućilo prodiranje u komplementarnu regiju ciljne molekule čime se dobija komplementarna regija jednolančanog ciljne molekule i susjedna regija; primjenu uzvodnog primera na jednolančanu regiju ciljne molekule i nastavak 3' kraja uzvodnog primera s polimerazom i dNTP da se proizvede ciljna molekula dvolančane nukleinske kiseline;
Apparatus for treating water at low cost, according to any one of claims 8 to 12, wherein the filtration means (3) comprises cartridge filters, sand filters, micro-filters, ultra-filters, nano-filters, or a combination thereof. 
Uređaj za obradu vode uz nizak trošak, prema bilo kojem prethodnom zahtjevu, naznačen time što sredstva za filtriranje (3) sadrže filterske uloške, pješčane filtre, mikro-filtre, ultra-filtre, nano-filtre, ili njihovu kombinaciju.
An activated cytotoxic T lymphocytes (CTL), produced by the method according to Claim 7, which selectively recognise a cell which aberrantly expresses a polypeptide comprising an amino acid sequence given in claim 1 or 2. 
Aktivirani citotoksični T-limfocit (CTL), proizveden metodom u skladu s patentnim zahtjevom 9 ili 10, koji selektivno prepoznaje peptid u skladu sa zahtjevom 1 ili 2.
The pharmaceutical compositions for separate administration of the combination partners and for the administration in a fixed combination, i.e., a single galenical composition comprising at least two combination partners, according to the invention can be prepared in a manner known per as and are those suitable for enteral, such as oral or rectal, and parenteral administration to mammals, including man, comprising a therapeutically effective amount of at least one pharmacologically active combination partner alone or in combination with one or more pharmaceutically acceptable carriers, especially suitable for enteral or parenteral application. 
Farmaceutski sastavi za odvojeno davanje kombinacije sudionika 1 za davanje u fiksnoj kombinaciji, tj. u obliku jednog galenskog sastava koji sadrži najmanje dva sudionika kombinacije prema izumu, mogu se pripraviti na način poznat kao takav 1 oni su prikladni za enteralno davanje, kao oralno ili rektalno, i parenteralno davanje sisavcima, uključiv čovjeku, a sadrže terapeutski učinkovitu količinu najmanje jednog farmakološki aktivnog sudionika kombinacije samog ili u kombinaciji s jednim ili više farmaccutski prihvatljivih nosača, posebno prikladnih za cnteralnu ili parcnteralnu primjenu.
rheumatoid arthritis; or vi) associated with gastronintestinal ulceration, wherein optionally the gastrointestinal ulceration is associated with infectious colitis, ischemic colitis, collagenous or lymphocytic colitis or necrotizing enterocolitis; 
reumatoidni artritis; ili vi) povezano sa gastrointestinalnom ulceracijom, pri čemu je gastrointestinalna ulceracija opcionalno povezana sa zaraznim kolitisom, iskemijskim kolitisom, kolagenim ili limfocitnim kolitisom ili nekrotizirajućim enterokolitisom;
Process according to claim 4, which further comprises continuing the reaction of the dimethyl ketal of atorvastatin tert.-butyl ester (I) with the acid for 3 to 24 h at the same temperature to conclude the reaction. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što se dodatno sastoji u nastavljanju reakcije dimetil-ketala fert-butilnog estera atorvastatina (1) s kiselinom u trajanju od 3 do 24 sata na istoj temperaturi kako bi se dovršilo reakciju.
Authentication method according to claim 1 or 2, wherein the Manager is associated to an electronic equipment in the form of a computer user terminal and the text messages exchanged between the Manager electronic equipment and the Intermediary electronic equipment are computer text messages, transported in particular using TCP/IP protocol. 
Postupak autentifikacije sukladno Zahtjevu 1 ili 2, pri čemu je Upravitelj povezan s elektroničkom opremom u obliku terminala korisnika računala, a tekstualne poruke razmijenjene između elektroničke opreme Upravitelja i elektroničke opreme Posrednika su računalne tekstualne poruke, prenesene posebice pomoću TCP/IP protokola.
The compound of claim 1, wherein the compound of formula I-B is or a pharmaceutically acceptable salt or stereoisomer thereof. 
Spoj formule 265 [image] ili njegova farmaceutski prihvatljiva sol, stereoizomer, hidrat, ili solvat.
the serine at position 129 is replaced with a glutamic acid and the serine at position 139 is replaced with an alanine, 
serin na položaju 129 je zamijenjen sa glutaminskom kiselinom i serin na položaju 139 je zamijenjen sa alaninom,
The pharmaceutical composition of embodiment 8, wherein said disease is selected from the group consisting of: gastric cancer, lung cancer, liver cancer, colorectal cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, sclerosing adenosis, uterine cancer, cervical cancer, head and neck cancer, esophagus cancer, thyroid cancer, parathyroid cancer, renal cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, blood cancer, lymphoma, fibroadenoma, inflammation, diabetes, obesity, psoriasis, rheumatoid arthritis, hemangioma, acute or chronic kidney disease, coronary restenosis, autoimmune diseases, asthma, neurodegenerative diseases, acute infection or ocular diseases caused by angiogenesis. 
Spoj ili pripravak za uporabu u skladu s patentnim zahtjevom 15, pri čemu je navedena bolest izabrana iz skupine koja se sastoji od: karcinoma želuca, karcinoma pluća, karcinoma jetre, kolorektalnog karcinoma, karcinoma tankog crijeva, karcinoma gušterače, karcinoma mozga, raka kostiju, melanoma, raka dojke, sklerozirajuće adenoze, raka maternice, raka grlića maternice, karcinoma glave i vrata, karcinoma jednjaka, karcinoma štitnjače, paratiroidnog karcinoma, karcinoma bubrega, sarkoma, karcinoma prostate, karcinoma uretre, karcinoma mokraćnog mjehura, karcinoma krvi, limfoma, fibroadenoma, upale, dijabetesa, pretilosti, psorijaze, reumatoidno g artritisa, hemangioma, akutne ili kronične bolesti bubrega, koronarne restenoze, autoimunih bolesti, astme, neurodegenerativnih bolesti, akutne infekcije ili očnih bolesti uzrokovanih angiogenezom.
is selected from the group consisting of fused 2-ring carbocyclyl and fused 2-ring heterocyclyl, wherein each such substituent is substituted with a substituent selected from the group consisting of RF and RJ; 
R* je odabran iz skupine koja sadrži pripojeni dvostruki karbociklilni prsten i pripojeni dvostruki heterociklilni prsten, gdje je svaki takav supstituent supstituiran sa supstituentom koji je odabran iz skupine koja sadrži R" i R';
The compounds of the invention may also be used for the treatment of allergic and vasomotor rhinitis. 
Spojevi formula (I) 1 (Ia) mogu se također upotrijebiti za liječenje alergijskog i vazomotornog Tinitisa.
In one embodiment of the methods provided above, culturing the one or more cells comprises batch cultivation of the cells. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se uzgoj jedne ili više stanica sastoji u šaržnom uzgoju stanica ili u kontinuiranom uzgoju stanica.
heating the solution to remove the water and cross-link the carboxymethylcellulose with the citric acid, thereby forming the polymer hydrogel; said polymer hydrogel having a swelling ratio in distilled water of at least 50. 
(b) zagrijavanje otopine radi uklanjanja vode i poprečnog povezivanja karboksimetilceluloze s limunskom kiselinom, pri čime se formira polimerni hidrogel; gdje navedeni polimerni hidrogel ima udio bubrenja u destiliranoj vodi od najmanje 50.
Ar is phenyl or pyridyl, which is unsubstituted or mono- or disubstituted by Hal, LA or O(LA), is Hal, LA, O(LA), Cyc1 or Cyc2, and pharmaceutically acceptable salts, solvates, solvates of salts, or prodrugs thereof. 
Ar je fenil ili piridil, koji je nesupstituiran ili mono- ili disupstituiran s Hal, LA ili O(LA), R' je Hal, LA, O(LA), Cyc! ili Cyc", ili njegova farmaceutski prihvatljiva sol, solvat ili solvat soli.
When the laminated disc 1 thus makes contact with the surface of the workpiece of a workpiece to be finished, a practically homogenous pressure will be exerted in the contact surface between said workpiece and the laminated workpiece 1, as already mentioned above. 
Kada lamelirani disk 1 čini na taj način kontakt s površinom komada koji se treba obraditi i koji se treba završno obraditi, stvara se praktički homogeni pritisak na površini kontakta između navedenog komada koji se treba obraditi i lameliranog diska 1, kao što je već bilo gore navedeno.
The progesterone for use of any one of the preceding claims, wherein the two-level intravenous dosing regime of progesterone results in a progesterone serum level in said subject of about 100 ng/ml to about 2000 ng/ml. 
Progesteron namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što dvorazinski intravenski režim doziranja progesterona resultira razinom progesterona u serumu kod navedenog subjekta od otprilike 100 ng/ml do otprilike 2000 ng/ml.
The apparatus of Claim 4, wherein the adaptation of the lower portion of the lower connector comprises either: 
Uređaj u skladu s patentnim zahtjevom 4, naznačen time što se podešavanje donjeg dijela donje spojnice sastoji bilo u tome što:
The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a HCDR1 having an amino acid sequence of SEQ ID NO: 84, a HCDR2 having an amino acid sequence of SEQ ID NO; 86, a HCDR3 having an amino acid sequence of SEQ ID NO: 88, a LCDR1 having an amino acid sequence of SEQ ID NO: 92, a LCDR2 having an amino acid sequence of SEQ ID NO: 94 and a LCDR3 having an amino acid sequence of SEQ ID NO: 96 
Izolirano antitijelo ili njegov fragment koji se vezuje za antigen prema patentnom zahtjevu 1, naznačen time, što antitijelo ili njegov fragment koji se vezuje za antigen sadrži HCDR1 koja ima aminokiselinsku sekvencu SEQ ID NO: 84, HCDR2 koja ima aminokiselinsku sekvencu SEQ ID NO: 86, HCDR3 koja ima aminokiselinsku sekvencu SEQ ID NO: 88, LCDR1 koja ima aminokiselinsku sekvencu SEQ ID NO: 92, LCDR2 koja ima aminokiselinsku sekvencu SEQ ID NO: 94 i LCDR3 koja ima aminokiselinsku sekvencu SEQ ID NO: 96.
Dextromethorphan when co-administered with tolperisone at ratios from 1:19 to 1:4 significantly increased the effect of tolperisone. 
Kad se dekstrometorfan dade zajedno s tolperisonom u omjerima od 1:19 do 1:4 on značajno povećava učinak tolperisona.
stands for hydrogen atom or for straight or branched C1-4 alkyl group, or C3-6 cycloalkyl group, or a phenyl- or thienyl-, or furyl group, optionally substituted with one or more, identical or different, straight or branched C1-4 alkyl group, straight or branched C1- 4 alkoxy group, hydroxyl group or halogen atom, or 
predstavlja atom vodika ili nerazgranatu ili razgranatu C1-4 alkilnu skupinu ili C3-6 cikloalkilnu skupinu, ili fenilnu ili tienilnu ili furilnu skupinu, izborno supstituiranu s jednom ili više, istovjetnih ili različitih, nerazgranatih ili razgranatih C1-4 alkilnih skupina, nerazgranatih ili razgranatih C1-4 alkoksi skupina, hidroksilnih skupina ili atoma halogena, ili
A pharmaceutical combination of Claim 28 wherein the glucosidase inhibitor is selected from acarbose and miglitol. 
Farmaceutski sastav Zahtjeva 28, naznačen time, da je inhibitor glukozidaze izabran od akarboze i miglitola.
The method according to claim 3 wherein the incubation step comprises adding unfermented cocoa beans to an ethanolic solution at a temperature of between 10°C and 70°C for a period of between 2 hours and 10 days, the volume of the ethanolic solution being sufficient to cover the cocoa beans. 
Komplet za proizvodnju čokolade ili čokoladi sličnih proizvoda u skladu s patentnim zahtjevom 1, naznačen time što se korak inkubiranja sastoji u dodavanju nefermentiranih zrna kakaa u etanolnu otopinu na temperaturi između 10 °C i 70 °C, u trajanju između 2 sata i 10 dana, gdje je volumen etanolne otopine dovoljan za pokrivanje zrna kakaa.